

**University of Pittsburgh
School of Medicine**

The Seventh Annual A. Julio Martinez Memorial Lecture

GUEST SPEAKER

Dr. Andreas von Deimling
Professor of Neuropathology
Director, Department of Neuropathology
Institute of Pathology
University of Heidelberg
Heidelberg, Germany

“Development and Relevance of the Tumor Biomarkers IDH1 and BRAF”

Wednesday, October 5, 2011

12:00 – 1:00 p.m.

Room 1105

UPMC Presbyterian Hospital
11th Floor Scaife Conference Center
200 Lothrop Street,
Pittsburgh, PA



Dr. Andreas von Deimling is Professor of Neuropathology at the University of Heidelberg. He also serves as Director of the Clinical Cooperation Unit Neuropathology at the German Cancer Research Center (DKFZ) in Heidelberg. He trained for Neuropathology at the University of Zurich, Switzerland, the Massachusetts General Hospital in Boston, USA, and the University of Bonn, Germany. From 1998 to 2006, prior to his move to Heidelberg, he was Director of the Institute of Neuropathology at the Charité Hospital, Berlin. Dr. von Deimling has special interest in human brain tumors including classification and grading aspects and their underlying molecular biology. He has been involved in the identification of biomarkers such as 1p/19q losses in oligodendroglial tumors and IDH1 mutations in diffuse gliomas. He has published over 270 peer reviewed research papers and is a member of the working group for the WHO *Classification of Tumors of the Central Nervous System*. Current projects address the function of IDH and BRAF mutations in brain tumors and their impact on diagnosis and therapy.